Is the Seattle boom going to hurt middle- and lower-income people’s housing options for years to come? How do we bridge the gender gap in pay? With its minimum wage law in place, how does Seattle continue to offer more people a chance at a decent living here?
Seattle City Councilmember Kshama Sawant and Liz Vivian, executive director of the Women’s Funding Alliance, will address these and other questions at these other questions at the next Civic Cocktail on April 6.
The event will also feature a discussion with Dr. Phil Greenberg, head of immunology at Fred Hutchinson Cancer Research Center, who has been researching new cancer treatments that have drawn worldwide attention.
The doors open at 5:30 p.m. on April 6 at the Tom Douglas’ Palace Ballroom, and the program starts at 6 p.m. Tickets for the event, co-sponsored by Crosscut with Seattle Channel and Seattle CityClub, are $20 for Crosscut, CityClub or KCTS9 members, $25 for the general public and $25 at the door. You can register here. We hope to see you there, but if for some reason you can’t make it, you can catch the program later on the Seattle Channel.
Veteran Seattle journalist Joni Balter will lead the discussion and bring in audience questions. Local journalists, including South Seattle Emerald’s Marcus Green, KPLU’s Gabe Spitzer and Crosscut’s Drew Atkins and Ruchika Tulshyan will also take part in the questioning.
In case you can’t attend, or if you just want to brush up on your knowledge, here’s a quick guide to the issues and speakers.
Pay, jobs and housing
“Murray goes big on housing levy,” Crosscut.
“$1 billion planned for cancer ‘moonshot,’” the New York Times.
“Why it’s too early to get excited about this ‘unprecedented’ new cancer treatment,” the Washington Post.
“Dramatic reductions seen in immunotherapy trial of blood cancer patients,” Fred Hutch News Service.
An earlier version of this article stated Dr. Stan Riddell would be speaking at Civic Cocktail. The story has been updated to reflect that Dr. Phil Greenberg will be featured on the upcoming show.